Spike Protein News and Research

RSS

Two potent SARS-CoV-2 neutralizing antibodies effective against B.1.351 and B.1.1.7 variants

By analyzing the cryoEM structures of antibodies against the SARS-CoV-2 virus, researchers report that the neutralizing capabilities of two antibodies are not affected by new strains as these antibodies target regions of the virus away from the ACE2 binding regions.

23 Feb 2021

Research predicts which mammal species can spread SARS-CoV-2

Scientists worldwide are fighting to contain the ongoing COVID-19 pandemic, which has already claimed more than 2.48 million lives. Preventing spillback infections is essential to containing the pandemic. To do so, it is vital to understand the nature of the virus, i.e., its susceptibility to a range of hosts.

23 Feb 2021

Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus

A randomized, placebo-controlled Phase 1 clinical trial of two monoclonal antibodies (mAbs) directed against the coronavirus that causes Middle East respiratory syndrome (MERS) found that they were well tolerated and generally safe when administered simultaneously to healthy adults.

23 Feb 2021

Key mutation sites in the SARS-CoV-2 spike protein modulate antibody and ACE2 affinity

A paper recently uploaded to the preprint server bioRxiv by researchers at Chapman University in California (Feb 22nd, 2021) utilized computational methods to screen severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutants for affinity with the angiotensin-converting enzyme 2 (ACE2) receptor and monoclonal antibodies REG10987 and REG10933.

23 Feb 2021

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

A new research paper recently uploaded to the preprint server bioRxiv by Jesse D. Bloom et al. (22nd Feb 2021) aims to map all of the currently circulating SARS-CoV-2 lineages with resistance towards LY-CoV555 and LY-CoV016, and document the specific mutations that confer resistance, ultimately suggesting that future monoclonal antibody cocktails should target a more diverse range of epitopes.

23 Feb 2021

GSK-3 inhibitors show promise in treating coronavirus infections

Researchers in the United States have suggested a new approach to treating infection with coronaviruses such as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) – the agent that causes coronavirus disease 2019 (COVID-19).

23 Feb 2021

Researchers develop nanoceutical mask fabric that prevents SARS-CoV-2 transmission

Researchers at S N Bose National Centre for Basic Sciences in West Bengal found that a nanoceutical fabric, which is comfortable, washable, and anti-microbial, can prevent the transmission of SARS-CoV-2.

23 Feb 2021

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

Scientists at the University of Salzburg and Pantec Biosolutions AG have developed a laser-facilitated epicutaneous immunization against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein. The model has induced angiotensin-converting enzyme 2 (ACE2) blocking antibodies in mice.

23 Feb 2021

How effective has Israel’s SARS-CoV-2 testing and vaccination campaign been against the UK variant?

A recent study by researchers at Tel Aviv University describes the UK variant’s rise to dominance in Israel. It also assesses the efficacy of the testing and vaccination programs employed by the government.

23 Feb 2021

L452R mutation potentially favors adaptive evolution of SARS-CoV-2

A team of scientists from the United States recently investigated the mutational signatures in the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.

23 Feb 2021

Could rotavirus vaccine platforms aid in the immunization campaign against SARS-CoV-2?

The study began with the generation of recombinant (r)SA11 rotaviruses, into which segment 7 modified RNAs were introduced. These encoded sequences for the non-structural protein NSP3 and some parts of the viral spike.

23 Feb 2021

Fooling the novel coronavirus with a fake handshake to inactivate the virus

Fool the novel coronavirus once and it can't cause infection of cells, new research suggests.

22 Feb 2021

CovMT could help researchers to track evolution of SARS-CoV-2 mutations

A SARS-CoV-2 tracker uses publicly available sequencing data to show how the virus is changing and spreading over time. The tracker, called CovMT, was developed at KAUST and is expected to help researchers and policymakers understand the evolution of the virus's mutations.

22 Feb 2021

WVU researchers set to identify SARS-CoV-2 variants, mitigate strain outbreaks

West Virginia University scientists knew it was coming. When health officials confirmed the first three cases of a COVID-19 variant in West Virginia late Friday (Feb. 19), they were not surprised.

22 Feb 2021

Seropositive individuals show similar antibody levels to a second mRNA vaccine dose

Seropositive individuals —people who received antibodies after COVID-19 infection — may be able to safely delay their second mRNA vaccine dose after all, according to the results of a new study.

22 Feb 2021

Researchers uncover 'hotspots' on the Spike protein that are critical for SARS-CoV-2 infection

The COVID-19 pandemic has prompted considerable investigation into how the SARS-CoV-2 Spike protein attaches to a human cell during the infection process, as this knowledge is useful in designing vaccines and therapeutics.

22 Feb 2021

Current monoclonal antibodies less potent against SARS-CoV-2 variants

Researchers at the New York University Grossman School of Medicine and Biohaven Pharmaceuticals found that the REGN10933 and REGN10987 combination was 9.1-fold less potent on the B.1.351 variant, which emerged in South Africa, and 16.2-fold less potent on mink cluster 5.

22 Feb 2021

An overview of spike protein antigen COVID-19 vaccine candidates

A new paper in the journal Reviews in Medical Virology provides a perspective on current vaccine development strategies and tools, which may allow the production of safe and effective vaccines.

22 Feb 2021

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

A new study sheds light on the threat posed by future zoonotic coronaviruses to make similar leaps across species barriers to infect human beings and cause other pandemics.

22 Feb 2021

Superspreader events trigger emergence of novel SARS-CoV-2 variants in USA

A team of scientists from the USA and Germany has recently studied the evolution of SARS-CoV-2 in a representative set of sequences from the USA collected between 2020 and 2021. The findings reveal that the viral genome has accumulated multiple mutations over time with only occasional loss of mutation. The main driving forces behind such genetic variations include widespread infection and superspreader events.

22 Feb 2021

Spike Protein News and Research

Two potent SARS-CoV-2 neutralizing antibodies effective against B.1.351 and B.1.1.7 variants

Research predicts which mammal species can spread SARS-CoV-2

Phase 1 clinical trial shows promising results for monoclonal antibodies against MERS coronavirus

Key mutation sites in the SARS-CoV-2 spike protein modulate antibody and ACE2 affinity

SARS-CoV-2 mutations allow escape from clinical monoclonal antibodies

GSK-3 inhibitors show promise in treating coronavirus infections

Researchers develop nanoceutical mask fabric that prevents SARS-CoV-2 transmission

Could laser-facilitated epicutaneous vaccination for SARS-CoV-2 be an alternative to intramuscular injection?

How effective has Israel’s SARS-CoV-2 testing and vaccination campaign been against the UK variant?

L452R mutation potentially favors adaptive evolution of SARS-CoV-2

Could rotavirus vaccine platforms aid in the immunization campaign against SARS-CoV-2?

Fooling the novel coronavirus with a fake handshake to inactivate the virus

CovMT could help researchers to track evolution of SARS-CoV-2 mutations

WVU researchers set to identify SARS-CoV-2 variants, mitigate strain outbreaks

Seropositive individuals show similar antibody levels to a second mRNA vaccine dose

Researchers uncover 'hotspots' on the Spike protein that are critical for SARS-CoV-2 infection

Current monoclonal antibodies less potent against SARS-CoV-2 variants

An overview of spike protein antigen COVID-19 vaccine candidates

COVID-19 vaccine candidate shows potential against SARS-CoV-2 and potential future zoonotic coronaviruses

Superspreader events trigger emergence of novel SARS-CoV-2 variants in USA

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News